Efficacy and safety of change the antiplatelet agent in patients with chronic noncardioembolic ischemic stroke - multi-center prospective study

Phase 4

• Conditions: noncardioembolic ischemic stroke

• Registration Number: JPRN-UMIN000004611
• Lead Sponsor: eurosurgery,Kawasaki Medical School

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-12-01
• Study Completion: 2015-03-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients with cardioembolic ischemic stroke. 2. Patients with hemorrhage or bleeding tendency. 3. Patients with congestive heart failure. 4. Patients with a history of hypersensitivity to ingredients of cilostazol. 5. Pregnant, possibly pregnant, or nursing women. 6. Patients on cilostazol 7. Patients with CAS for asymptomatic stroke. 8. Patients during the argatroban, ozagrel sodium or scheduled. 9. Patients during the rt-PA or scheduled. 10. Patients with scheduled on neuroendovascular therapy. 11. Patients on experimental drug or scheduled. 12. Patients who are otherwise judged inappropriate for inclusion in the study by the investigators.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Episode of headache, palpitation, tachycardia.

Secondary Outcome Measures

Name	Time	Method
1. Withdrawal for adverse effect. (headache, palpitation, tachycardia) 2. Episode of adverse effect to exclusion of headache, palpitation, tachycardia. 3.Change of mRS.